Top

World Journal of Urology

Published in:

Open Access 01-06-2009 | Topic Paper

Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo^® working party

Authors: J. Alfred Witjes, Kees Hendricksen, O. Gofrit, O. Risi, O. Nativ

Published in: World Journal of Urology | Issue 3/2009

Abstract

Objectives

To study the results of chemotherapy combined with intravesical hyperthermia in patients with mainly BCG-failing carcinoma in situ (CIS).

Methods

Patients with histologically confirmed CIS were included retrospectively. Outpatient thermochemotherapy treatment was done with mitomycin-C (MMC) and the Synergo^® system SB-TS 101 (temperature range between 41 and 44°C), weekly for 6–8 weeks, followed by 4–6 sessions every 6–8 weeks.

Results

Fifty-one patients were treated between 1997 and 2005 from 15 European centers. Thirty-four were pre-treated with BCG. Mean age was 69.9 years. Twenty-four patients had concomitant papillary tumors. The mean number of hyperthermia/MMC treatments per patient was 10.0. Of the 49 evaluable patients 45 had a biopsy and cytology proven complete response. In two patients CIS disappeared, but they had persistent papillary tumors. Follow-up of 45 complete responders showed 22 recurrences after a mean of 27 months (median 22): T2 (4), T1 (4), T1/CIS (1), CIS (5), Ta/CIS (2), Ta (5) and Tx (1). Side effects (bladder complaints) were generally mild and transient.

Conclusions

In patients with primary or BCG-failing CIS, treatment with intravesical hyperthermia and MMC appears a safe and effective treatment. The initial complete response rate is 92%, which remains approximately 50% after 2 years.

Park J, Song C, Hong JH, Park BH, Cho YM, Kim CS, Ahn H (2009) Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer. World J Urol. doi:10.1007/s00345-008-0350-4

Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–5. doi:10.1016/j.eururo.2005.12.031

Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M (2008) Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 53:146–152. doi:10.1016/j.eururo.2007.06.030 PubMedCrossRef

Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y (2007) Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 51:152–160. doi:10.1016/j.eururo.2006.08.037 PubMedCrossRef

Griffiths TR, Charlton M, Neal DE, Powell PH (2002) Treatment of carcinoma in situ with intravesical bacillus Calmette–Guerin without maintenance. J Urol 167:2408–2412. doi:10.1016/S0022-5347(05)64994-4 PubMedCrossRef

van der Meijden AP, Sylvester R, Oosterlinck W et al (2005) EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 48:363–371PubMed

Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr, Schellhammer PF (2007) Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178:2314–2330. doi:10.1016/j.juro.2007.09.003 PubMedCrossRef

Witjes JA (2006) Management of BCG failures in superficial bladder cancer: a review. Eur Urol 49:790–797. doi:10.1016/j.eururo.2006.01.017 PubMedCrossRef

Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M (2000) Efficacy and safety of valrubicin for the treatment of Bacillus Calmette–Guerin refractory carcinoma in situ of the bladder. The valrubicin study group. J Urol 163:761–767. doi:10.1016/S0022-5347(05)67799-3 PubMedCrossRef

10.

Dalbagni G, Russo P, Sheinfeld J et al (2002) Phase I trial of intravesical gemcitabine in bacillus Calmette–Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 20:3193–3198. doi:10.1200/JCO.2002.02.066 PubMedCrossRef

11.

Morales A (2008) Evolution of intravesical immunotherapy for bladder cancer: mycobacterial cell wall preparation as a promising agent. Expert Opin Investig Drugs 17:1067–1073. doi:10.1517/13543784.17.7.1067 PubMedCrossRef

12.

O’Donnell MA, Krohn J, DeWolf WC (2001) Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette–Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette–Guerin alone previously failed. J Urol 166:1300–1304. doi:10.1016/S0022-5347(05)65757-6 (discussion)PubMedCrossRef

13.

Berger AP, Steiner H, Stenzl A, Akkad T, Bartsch G, Holtl L (2003) Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology 61:338–341. doi:10.1016/S0090-4295(02)02123-4 PubMedCrossRef

14.

Di Stasi SM, Giannantoni A, Giurioli A et al (2006) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 7:43–51. doi:10.1016/S1470-2045(05)70472-1 PubMedCrossRef

15.

Colombo R, Da Pozzo LF, Lev A, Freschi M, Gallus G, Rigatti P (1996) Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 155:1227–1232. doi:10.1016/S0022-5347(01)66225-6 PubMedCrossRef

16.

Colombo R, Da Pozzo LF, Salonia A et al (2003) Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 21:4270–4276. doi:10.1200/JCO.2003.01.089 PubMedCrossRef

17.

Gofrit ON, Shapiro A, Pode D et al (2004) Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 63:466–471. doi:10.1016/j.urology.2003.10.036 PubMedCrossRef

18.

van der Heijden AG, Kiemeney LA, Gofrit ON et al (2004) Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 46:65–71. doi:10.1016/j.eururo.2004.01.019 PubMedCrossRef

19.

Colombo R, Lev A, Da Pozzo LF, Freschi M, Gallus G, Rigatti P (1995) A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J Urol 153:959–963. doi:10.1016/S0022-5347(01)67613-4 PubMedCrossRef

20.

Newling DW, Hetherington J, Sundaram SK, Robinson MR, Kisbenedek L (2001) The use of valrubicin for the chemoresection of superficial bladder cancer—a marker lesion study. Eur Urol 39:643–647. doi:10.1159/000052521 PubMedCrossRef

21.

Bartoletti R, Cai T, Gacci M et al (2005) Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology 66:726–731. doi:10.1016/j.urology.2005.04.062 PubMedCrossRef

22.

Dalbagni G, Russo P, Bochner B et al (2006) Phase II trial of intravesical gemcitabine in bacille Calmette–Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24:2729–2734. doi:10.1200/JCO.2005.05.2720 PubMedCrossRef

23.

Sarosdy MF, Manyak MJ, Sagalowsky AI et al (1998) Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guerin. Urology 51:226–231. doi:10.1016/S0090-4295(97)00510-4 PubMedCrossRef

24.

Joudi FN, Smith BJ, O’Donnell MA (2006) Final results from a national multicenter phase II trial of combination bacillus Calmette–Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24:344–348. doi:10.1016/j.urolonc.2005.11.026 PubMed

25.

Waidelich R, Stepp H, Baumgartner R, Weninger E, Hofstetter A, Kriegmair M (2001) Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 165:1904–1907. doi:10.1016/S0022-5347(05)66239-8 PubMedCrossRef

26.

Colombo R, Brausi M, Da PL et al (2001) Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication: a pilot study on marker lesion. Eur Urol 39:95–100. doi:10.1159/000052419 PubMedCrossRef

27.

Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ (1999) 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette–Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian bladder cancer study group. J Urol 161:1124–1127. doi:10.1016/S0022-5347(01)61607-0 PubMedCrossRef

28.

Hautmann RE, Stein JP (2005) Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. Urol Clin North Am 32:177–185. doi:10.1016/j.ucl.2005.02.001 PubMedCrossRef

29.

Witjes JA, Kiemeney LA, Schaafsma HE, Debruyne FM (1994) The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Br J Urol 73:172–176. doi:10.1111/j.1464-410X.1994.tb07487.x PubMedCrossRef

Title: Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo® working party
Authors: J. Alfred Witjes
Kees Hendricksen
O. Gofrit
O. Risi
O. Nativ
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 3/2009
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-009-0384-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo^® working party

Abstract

Objectives

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2009

TGFB1 gene polymorphism Leu10Pro (c.29T>C), prostate cancer incidence and quality of life in patients treated with brachytherapy

The present and future burden of urinary bladder cancer in the world

Experimental animal model and RNA interference: a promising association for bladder cancer research

The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience

Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer

Impact of preoperative haemoglobin concentrations on the efficiency of KTP-laser vaporization of the prostate